Full Text
Cost-Effectiveness of Ruxolitinib for The Treatment of Myelofibrosis In Finland. Economic Evaluation Based on Finnish Auria Biobank Data on Health Care Resource Utilization

Abstract

Authors

J Hahl S Kurki T Miettinen K Snicker

Back to Volume 18, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×